KIZ-related Retinopathy (Retinitis Pigmentosa 69): Comprehensive Disease Characterization

Disease: KIZ-related Retinopathy | **MONDO:** MONDO:0700232 | **OMIM:** #615780 (Retinitis pigmentosa 69) **Causal gene: KIZ** (kizuna / PLK1S1), OMIM *615757, HGNC:20738, chr20p11.23* | *Category:** Mendelian, autosomal recessive

Summary

KIZ-related Retinopathy is Retinitis Pigmentosa 69 (RP69), a rare, non-syndromic autosomal recessive rod-cone dystrophy caused by biallelic loss-of-function variants in the gene KIZ (encoding the centrosomal protein kizuna, also called PLK1S1). The causal gene is **KIZ** — this must be stated explicitly because the serial disease name "retinitis pigmentosa 69" does not itself name the gene, and the retinitis pigmentosa series spans >80 distinct genes. KIZ sits on chromosome 20p11.23, encodes a 673-amino-acid Polo-like kinase 1 (Plk1) substrate, and in post-mitotic photoreceptors localizes to the **basal body of the connecting cilium**, placing RP69 among the **ciliopathies of outer-segment maintenance**.

The disease was first defined in 2014 by whole-exome sequencing of a consanguineous family, which identified the homozygous nonsense allele **c.226C>T (p.Arg76*)** [PMID: 24680887]. This allele is an **Ashkenazi Jewish founder mutation**: gnomAD v4 shows it is enriched ~65-fold in Ashkenazi Jews (allele frequency 5.76×10^{-3}, carrier frequency ~1.15%, ~1 in 87) versus non-Finnish Europeans. It acts through a **dual molecular mechanism** — a premature stop codon plus disruption of an exonic splicing enhancer (ESE) that causes pronounced skipping of exon 3 — which has the clinical implication that RNA-based (splice-modulating) therapies are predicted to be of low efficacy [PMID: 38927740].

Clinically, RP69 is an **early-onset but comparatively mild and slowly progressive** rod-cone dystrophy: patients present with night blindness and progressive peripheral field loss, show classic rod-cone ERG abnormalities, hyperautofluorescent rings, and expanding RPE atrophy, yet retain central ellipsoid-zone and cone function longer than patients with DHDDS- or

FAM161A-associated RP. There is **no gene-specific therapy**; management is supportive (e.g., carbonic anhydrase inhibitors for cystoid macular edema, low-vision support, genetic counseling). This report synthesizes seven confirmed findings across 15 reviewed papers and maps them onto the full disease-characterization template.

Key Findings

Finding 1 — RP69 is an autosomal recessive retinitis pigmentosa caused by biallelic loss-of-function in KIZ

Whole-exome sequencing of a consanguineous family with autosomal-recessive rod-cone dystrophy identified a homozygous nonsense mutation **c.226C>T (p.Arg76*)** in *KIZ*, which encodes centrosomal protein kizuna. Sanger screening of 340 additional AR/sporadic rod-cone dystrophy cases uncovered two more affected individuals: one homozygous for p.Arg76* and one compound heterozygous for **c.119_122delAACT (p.Lys40Ilefs*14)** and **c.52G>T (p.Glu18*)** [PMID: 24680887]. The disease is catalogued as **Retinitis pigmentosa 69, OMIM #615780**; the gene as *KIZ*, OMIM *615757, HGNC:20738, on chromosome 20p11.23.

> "identified a homozygous nonsense mutation, c.226C>T (p.Arg76(∗)), in KIZ, which encodes centrosomal protein kizuna" — PMID: 24680887

This establishes KIZ as the causal gene and anchors the disease firmly in the recessive rod-cone dystrophy / retinitis pigmentosa category. **Suggested ontology terms:** MONDO:0700232; HP:0000510 (Rod-cone dystrophy), HP:0000512 (Abnormal electroretinogram); gene HGNC:20738.

Finding 2 — c.226C>T (p.Arg76*) is an Ashkenazi Jewish founder allele acting through a dual (nonsense + exon-3-skipping) mechanism

In the largest reported cohort to date, **31 patients with biallelic KIZ mutations** were characterized: 28 were homozygous for c.226C>T (p.Arg76*), 2 were compound heterozygous for p.Arg76* / c.3G>A (p.Met1?), and 1 was homozygous for c.247C>T (p.Arg83*) [PMID: 38927740]. The founder allele lies within an **exonic splicing enhancer (ESE)**, and the C>T change produces not only a premature stop codon but also **pronounced skipping of exon 3**.

> "Thirty-one patients with biallelic KIZ mutations were identified: 28 homozygous for c.226C>T (p.R76*)" — PMID: 38927740
>
> "c.226C>T is a founder mutation among patients of Jewish descent." — PMID: 38927740
>
> "p.R76* affect an ESE which in turn results in the pronounced skipping of exon 3. Therefore, RNA-based therapies might show low efficacy" — PMID: 38927740

This dual mechanism is therapeutically important: because the pathogenic transcript is already mis-spliced (exon 3 skipped), antisense/splice-correcting strategies targeting the point mutation are predicted to have **low efficacy**.

Finding 3 — RP69 is early-onset and progressive but milder than DHDDS/FAM161A RP, with measurable annual decline

Multimodal imaging of KIZ patients reveals classic rod-cone dysfunction on ERG, **outer-retinal atrophy with a centrally preserved ellipsoid zone (EZ)**, hyperautofluorescent rings, and surrounding loss of autofluorescence. Quantitatively, peripheral RPE atrophy area increased **~4.9%/year**, visual acuity declined at a mean exponential rate of **8.5%/year**, 30-Hz flicker amplitude declined **15.9%/year**, and EZ width shrank **~66.5 µm/year** [PMID: 32052671].

> "KIZ-associated RP is an early-onset severe rod-cone dystrophy." — PMID: 32052671
>
> "The RPE atrophy area increased annually by 4.9%" — PMID: 32052671

In the 31-patient cohort, clinical parameters were **less severe in KIZ than in DHDDS and FAM161A** patients [PMID: 38927740]. A 62-year-old homozygous for the start-codon variant **c.3G>A (p.Met1?)** retained measurable cone responses with macular sparing into the seventh decade, expanding the mild end of the clinical spectrum [PMID: 41557064].

Imaging / functional metric	Annual rate of change	Source
Peripheral RPE atrophy area	+4.9 %/yr	P 32052671
Best-corrected visual acuity (exponential)	−8.5 %/yr	P 32052671
30-Hz flicker ERG amplitude (exponential)	−15.9 %/yr	P 32052671
Ellipsoid zone width	−66.5 µm/yr	P 32052671

Suggested HPO terms: HP:0000662 (Nyctalopia / night blindness), HP:0001133 (Constriction of peripheral visual field), HP:0000546 (Retinal degeneration), HP:0007843 (Attenuation of retinal blood vessels), HP:0040049 (Macular edema), HP:0000512 (Abnormal electroretinogram), HP:0030506 (Yellow/white lesions of the retina).

Finding 4 — KIZ/kizuna is a Plk1-substrate centrosomal protein localizing to the photoreceptor connecting-cilium basal body; the disease is a ciliopathy of outer-segment maintenance

Kizuna (Kiz) was originally identified as a **centrosomal substrate of Plk1** whose phosphorylation maintains mitotic spindle-pole and pericentriolar-material (PCM) integrity; its depletion causes **centrosome fragmentation and multipolar spindles** [PMID: 16980960, P 17011480].

In post-mitotic photoreceptors, immunohistology localizes KIZ to the **basal body of primary cilia** in human fibroblasts [PMID: 24680887], and the mouse ortholog PLK1S1 localizes to the base of the photoreceptor connecting cilium. KIZ expression is highest in retina; *Plk1s1* mRNA is present in the outer nuclear layer / rod photoreceptors and declines as photoreceptors degenerate in *rd1* mice [PMID: 24680887, P 29057815].

> "we identify a novel centrosomal substrate of Plk1, Kizuna (Kiz), depletion of which causes fragmentation and dissociation of the pericentriolar material from centrioles at prometaphase, resulting in multipolar spindles" — PMID: 16980960

> "Immunohistology revealed KIZ localization at the basal body of the cilia in human fibroblasts" — PMID: 24680887

Importantly, patient fibroblasts showed **preserved KIZ localization and normal cilium length**, indicating fibroblasts are a poor disease model and that the pathology is photoreceptor-specific [PMID: 29057815]. **Suggested ontology terms:** GO:0007098 (centrosome cycle), GO:0051225 (spindle assembly), GO:0060271 (cilium assembly), GO:0120197 (photoreceptor outer segment organization); cellular components GO:0005813 (centrosome), GO:0036064 (ciliary basal body), GO:0005929 (cilium); cell type CL:0000210 (photoreceptor cell), CL:0000604 (retinal rod cell).

Finding 5 — gnomAD v4 quantifies the Ashkenazi founder effect (~1.15% carrier frequency) and confirms global rarity

gnomAD v4.1 genomes show the founder nonsense allele **c.226C>T / p.Arg76* (20-21136463-C-T)** at a **global allele frequency of 3.16×10^{-4}** (AC 48/152,128) but an **Ashkenazi Jewish AF of 5.76×10^{-3}** (AC 20/3,472) — roughly **65× the non-Finnish European AF (8.82×10^{-5})**. This corresponds to a heterozygous **carrier frequency of ~1.15% (≈1 in 87)** and a Hardy-Weinberg-predicted homozygote disease incidence of **~3.3×10^{-5} (~1 in 30,000)** in Ashkenazim from this allele alone. Other pathogenic alleles are much rarer: c.119_122del (p.Lys40Ilefs*14) global AF 8.5×10^{-5}; c.247C>T (p.Arg83*), c.52G>T (p.Glu18*), and c.3G>A (p.Met1?) each ≤7×10^{-6} globally (c.3G>A reaches asj AF ~2.9×10^{-4}). **No homozygotes** are listed in gnomAD, consistent with a recessive disease allele depleted in population reference databases.

Allele	Protein	Global AF	Ashkenazi (asj) AF	Notes
c.226C>T	p.Arg76*	3.16×10^{-4}	5.76×10^{-3}	Founder; ESE/exon-3 skipping
c.119_122del	p.Lys40Ilefs*14	8.5×10^{-5}	—	Frameshift
c.247C>T	p.Arg83*	≤7×10^{-6}	—	Nonsense
c.52G>T	p.Glu18*	≤7×10^{-6}	—	Nonsense
c.3G>A	p.Met1?	≤7×10^{-6}	~2.9×10^{-4}	Start-loss

Finding 6 — ClinVar/UniProt: ~30 pathogenic/likely-pathogenic alleles, predominantly loss-of-function, in a largely disordered centrosomal protein

ClinVar (KIZ[gene], 593 records) contains **15 Pathogenic + 12 Likely pathogenic + 3 Pathogenic/Likely-pathogenic** variants distributed along the gene, almost all loss-of-function: nonsense (e.g., c.805A>T p.Lys269*, c.1390C>T p.Gln464*, c.943A>T p.Arg315*, c.1316C>G p.Ser439*), frameshift (e.g., c.1119dup, c.875dup, c.305_309dup, c.62_65del), and canonical splice-site variants (c.1042+1G>T, c.153-1G>C, c.405+1dup, c.1353-1G>C). Contiguous-gene 20p CNV deletions appear in ClinVar but represent **multigene syndromes, not isolated KIZ retinopathy**. UniProt **Q2M2Z5 (KIZ_HUMAN, 673 aa)** annotates KIZ as a centrosomal protein that stabilizes expanded pericentriolar material and localizes to both the centrosome/MTOC and the cilium basal body; the protein is **largely intrinsically disordered** (5 disordered regions) with InterPro domains **IPR060349 (Kizuna_N)** and **IPR026742 (Centrosomal_kizuna)**. The uniform LoF spectrum across the whole gene strongly supports a **haploinsufficiency/ complete-loss-of-function** disease mechanism rather than dominant-negative or gain-of-function.

Finding 7 — KIZ is a rare, long-tail IRD gene, with conserved orthologs for modeling

In the nationwide **Israeli IRD consortium** cohort (2,420 families / 3,413 individuals, ~40% of Israeli IRD patients; RP 43%; AR 60%), the most frequently mutated genes were **ABCA4, USH2A, FAM161A, CNGA3, and EYS** — KIZ is not among the top genes, placing it in the rare long tail [PMID: 31456290]. Similarly, the **Foundation Fighting Blindness Consortium** gene poll (33,834 patients / 27,561 families) found top etiologies ABCA4 (17%), USH2A (9%), RPGR (6%), PRPH2 (5%), RHO (4%), with the top 100 genes explaining 94.4% of cases — KIZ again outside the top ranks [PMID: 39908130]. NCBI orthologs of human *KIZ* (GeneID 55857): **mouse *Kiz* (228730), rat *Kiz* (311502), dog *KIZ* (477134), zebrafish *kiz* (567100)** — a conserved toolkit for future disease modeling.

Mechanistic Model / Interpretation

Ordered causal chain (initiating lesion → clinical manifestation)

1. A **biallelic loss-of-function variant in KIZ** (most commonly the founder nonsense c.226C>T / p.Arg76*) **leads to** absent or truncated, non-functional kizuna protein. *(Demonstrated: nonsense/frameshift/splice alleles; the founder allele additionally disrupts an ESE causing exon-3 skipping —* P 24680887 P 38927740 *.)*
2. Loss of functional kizuna **results in** deficient stabilization of the **pericentriolar material / centrosome–basal-body apparatus**, the role established for kizuna in mitotic cells. *(Demonstrated in dividing cells —* P 16980960 P 17011480 *; inferred for post-mitotic photoreceptors.)*
3. In photoreceptors, kizuna normally localizes to the **basal body of the connecting cilium**; its loss **leads to** impaired integrity/maintenance of the connecting cilium that gates protein transport to the outer segment. *(Localization demonstrated —* P 24680887 P 29057815 *; functional consequence inferred.)*
4. Impaired connecting-cilium / basal-body function **results in** defective **outer-segment maintenance and renewal** in rods (and later cones). *(Inferred from ciliopathy framework; supported by declining Plk1s1 expression as photoreceptors degenerate in rd1 mice —* P 29057815 *.)*
5. Progressive outer-segment failure **leads to rod photoreceptor dysfunction then death**, clinically night blindness and peripheral field constriction, with abnormal rod-cone ERG. *(Demonstrated clinically —*

P 32052671

P 41557064

.)

6. Photoreceptor loss **results in** secondary **retinal pigment epithelium (RPE) atrophy** that expands centripetally (~4.9%/yr), with eventual cone involvement — but the fovea/EZ is relatively **spared longer** than in DHDDS/FAM161A RP, yielding a comparatively mild course. *(Demonstrated —*

P 32052671

P 38927740

P 41557064

.)

```
KIZ biallelic LoF (p.Arg76* + ESE/exon-3 skip)
        │
        ▼
Loss of functional kizuna protein (673 aa, disordered centrosomal protein)
        │
        ▼
Deficient PCM / centrosome–basal-body stabilization  ◄── canonical Plk1-substrate role
        │
        ▼
Impaired connecting-cilium basal body in photoreceptors
        │
        ▼
Defective outer-segment maintenance / protein transport
        │
        ├──► Rod dysfunction → night blindness, peripheral field loss, abnormal ERG
        │
        ▼
Rod death → secondary RPE atrophy (expanding ring)
        │
        ▼
Later cone involvement (EZ/fovea relatively spared → milder than DHDDS/FAM161A)
```

Upstream vs downstream: The mutation and loss of kizuna's centrosomal/basal-body stabilizing function are upstream; outer-segment failure, photoreceptor death, and RPE atrophy are downstream. **Cell types:** retinal rod photoreceptors (CL:0000604) first, then cone photoreceptors (CL:0000573) and RPE cells (CL:0002586). **Subcellular compartments:** ciliary basal body (GO:0036064), centrosome (GO:0005813), connecting cilium/photoreceptor cilium

(GO:0032391). **Key uncertainty:** the precise post-mitotic function of kizuna at the connecting cilium (steps 3–4) is **inferred by localization rather than directly demonstrated**; patient fibroblasts have normal cilia, underscoring a photoreceptor-specific requirement not yet mechanistically dissected.

Mapping to the Research Template

1. Disease information. Non-syndromic AR rod-cone dystrophy = Retinitis Pigmentosa 69. Identifiers: MONDO:0700232; OMIM #615780; gene OMIM *615757; HGNC:20738. Synonyms: RP69; KIZ-related retinitis pigmentosa; KIZ-associated rod-cone dystrophy. Information is drawn from aggregated disease-level resources** (OMIM, ClinVar, gnomAD, UniProt) plus individual-patient case series/cohorts (P 24680887 P 32052671 P 38927740 P 41557064).

2. Etiology. Purely **genetic** — biallelic loss-of-function variants in KIZ; no environmental, infectious, or toxic cause. Principal genetic risk factor is **Ashkenazi Jewish ancestry carrying p.Arg76*** (~1.15% carrier rate; consanguinity increases homozygosity risk). No established protective alleles or gene–environment interactions. Modifier genes are unknown.

3. Phenotypes. Night blindness (HP:0000662), peripheral visual-field constriction (HP:0001133), progressive retinal degeneration/RPE atrophy (HP:0000546), attenuated vessels (HP:0007843), abnormal/rod-cone ERG (HP:0000512), hyperautofluorescent ring, occasional cystoid macular edema (HP:0040049). **Onset:** early (childhood/young adult); **progression:** slow–moderate, progressive; **severity:** variable, generally milder than DHDDS/FAM161A RP; retained cone responses possible into the 7th decade (P 41557064). QoL impact: progressive visual disability affecting mobility and reading, but with longer central-vision preservation than many RP forms.

4. Genetic/molecular. Causal gene KIZ; ~30 P/LP ClinVar alleles, predominantly nonsense/frameshift/splice (LoF). Variant classification per ACMG; founder c.226C>T (p.Arg76*) is pathogenic. Allele frequencies per gnomAD (Finding 5). **Germline**, recessive; functional consequence = **loss of function** (not dominant-negative). Epigenetic modifiers: none established. Contiguous 20p deletions are multigene, not isolated RP69.

5. Environmental. Not applicable — no environmental, lifestyle, or infectious contributors identified for this Mendelian disease.

6. Mechanism. See causal chain above. Pathways: Plk1 centrosomal signaling; cilium assembly/maintenance. GO: GO:0060271 (cilium assembly), GO:0120197 (photoreceptor outer segment organization), GO:0007098 (centrosome cycle).

7. Anatomical structures. Primary organ: **eye/retina** (UBERON:0000970 eye, UBERON:0000966 retina); specifically photoreceptor layer and RPE; connecting cilium basal body (subcellular). Body system: visual/sensory nervous system. **Bilateral**, generally symmetric. Secondary: RPE atrophy. Cells: rod then cone photoreceptors, RPE.

8. Temporal development. Onset early (pediatric–young adult), insidious/chronic; progressive course; lifelong, no remission; critical window for future gene-based intervention is before advanced photoreceptor loss (EZ still preserved).

9. Inheritance and population. Autosomal recessive; penetrance appears high/complete when biallelic; variable expressivity (mild–moderate). **Founder effect** in Ashkenazi Jews (p.Arg76*, carrier ~1.15%, predicted homozygote incidence ~1 in 30,000 in that population); **consanguinity** contributes elsewhere. Rare globally (long-tail IRD gene). No sex predilection expected (autosomal).

10. Diagnostics. Genetic testing is definitive: IRD gene panels / whole-exome / whole-genome sequencing; single-gene or targeted founder-allele testing in Ashkenazi patients (P 24680887 ; WGS/splice context P 34795310). Phenotyping: full-field ERG (rod-cone pattern), SD-OCT (outer-retinal thinning, EZ constriction, possible CME), fundus autofluorescence (hyperAF ring, surrounding hypoAF), dilated fundus exam (disc pallor, vessel attenuation, bone-spicule/peripheral pigment). Differential diagnosis: other AR RP genes (USH2A, EYS, FAM161A, DHDDS) — distinguished by genetics and relative severity.

11. Outcome/prognosis. Non-fatal; **no effect on life expectancy**. Morbidity = progressive visual impairment, variable but often milder than other RP forms; central vision and cone function can persist for decades. Prognostic factors: genotype (e.g., milder with retained cones in p.Met1? case), EZ width, age. No validated molecular prognostic biomarkers beyond imaging metrics.

12. Treatment. No gene-specific or disease-modifying therapy. Supportive/symptomatic: carbonic anhydrase inhibitors (e.g., topical dorzolamide) for cystoid macular edema (used in [P 41557064]); low-vision rehabilitation; genetic counseling. **RNA-based/splice-correcting therapies predicted to be low-efficacy for the founder allele** because the mutant transcript already skips exon 3 ([P 38927740]). No approved gene therapy; AAV gene augmentation is conceptually plausible given LoF mechanism but unproven. NCIT suggestions: carbonic anhydrase inhibitor therapy; gene therapy (investigational).

13. Prevention. Primary prevention is genetic: **carrier screening** (Ashkenazi Jewish panels including p.Arg76*), cascade testing of relatives, preimplantation/prenatal genetic diagnosis, and **genetic counseling** (NSGC/ACMG; relevance supported by [P 39946424]). No behavioral, immunization, or public-health prevention applies.

14. Other species / natural disease. Conserved orthologs: mouse *Kiz* (NCBI GeneID 228730), rat *Kiz* (311502), dog *KIZ* (477134), zebrafish *kiz* (567100). No well-documented naturally occurring KIZ retinopathy in companion animals/wildlife reported; comparative/evolutionary conservation of the centrosomal function is strong. Not zoonotic.

15. Model organisms. Mouse (*Plk1s1/Kiz*) is the principal model; mRNA in outer nuclear layer/rod photoreceptors, with expression declining during degeneration in *rd1* mice ([P 29057815]). **Patient fibroblasts are a poor model** (normal cilium length, preserved localization) — [P 29057815]. Zebrafish and dog orthologs available for future knockout/knock-in modeling; iPSC-derived retinal organoids would be a logical photoreceptor-specific system.

Evidence Base

PMID	Title (abbrev.)	Evidence type	Role
24680887	WES identifies KIZ as a ciliary gene in AR rod-cone dystrophy	Human genetics + histology	**Defines the disease**: founder nonsense p.Arg76*, basal-body localization
38927740	Genetic & clinical analyses of KIZ (31-patient cohort)	Human cohort	Founder effect, dual ESE/exon-3-skipping mechanism, milder than DHDDS/FAM161A
32052671	Progressive RPE atrophy & photoreceptor death in KIZ RP	Human longitudinal imaging	Quantitative progression rates
41557064	Retained cone responses, homozygous start-codon variant	Human case report	Expands mild spectrum; dorzolamide management
29057815	Further insights into KIZ / murine PLK1S1	Human + mouse	Fibroblasts poor model; retinal expression dynamics
16980960	Plk1 target Kizuna stabilizes mitotic centrosomes	In vitro cell biology	Canonical centrosomal function
17011480	"Sealed with a Kiz": Plk1 & spindle-pole integrity	Review	Supports centrosomal mechanism
25558830	Kizuna is a mitotic substrate for CDC25B	In vitro	Additional regulatory context
31272276	Clathrin pT606 / GAK–PLK1–Kiz axis	In vitro	Kizuna phospho-regulation
21839059	Poloxin PBD inhibitor, Kizuna dysfunction	In vitro / in vivo	Kizuna in centrosome fragmentation
31456290	Nationwide Israeli IRD consortium	Human epidemiology	KIZ is a long-tail gene; founder-mutation context
39908130	FFB Consortium gene poll	Human epidemiology	Top IRD genes; KIZ rarity
34795310		Human genetics	

PMID	Title (abbrev.)	Evidence type	Role
	WGS + splice assays for IRDs		Diagnostic context for noncoding/ splice variants
39946424	Genetic counselling in inherited eye diseases	Human epidemiology	Counseling/testing relevance
32307445	ABCA4 dark matter (Stargardt)	Human genetics	Comparative IRD methodology

The in vitro/cell-biology papers (16980960, 17011480, 25558830, 31272276, 21839059) consistently define kizuna's **centrosomal/PCM-stabilizing** role but address dividing cells; they **support** the upstream mechanism while leaving the **post-mitotic photoreceptor function inferred** — the principal mechanistic gap. The clinical papers (24680887, 32052671, 38927740, 41557064) provide concordant, quantitative human evidence; no paper contradicts the core LoF-ciliopathy model.

Limitations and Knowledge Gaps

- **Post-mitotic mechanism is inferred, not proven.** Kizuna's photoreceptor-specific function at the connecting-cilium basal body is established by localization, not by functional assays in rods; the leap from "centrosomal PCM stabilizer in mitosis" to "outer-segment maintenance in post-mitotic photoreceptors" remains a hypothesis.
- **No in vivo retinal disease model has been reported** showing recapitulation of the human degeneration; patient fibroblasts are explicitly a poor model (normal cilia).
- **Natural history is based on small cohorts** (largest n = 31) from populations enriched for the single founder allele, limiting genotype–phenotype generalizability for non-founder variants.
- **Penetrance, expressivity, and modifier genes are poorly quantified**; the basis for RP69 being milder than DHDDS/FAM161A RP is not mechanistically explained.
- **Epidemiology outside Ashkenazi Jewish populations is essentially unknown**; global prevalence is extrapolated from gnomAD allele frequencies, not measured.
- **No approved or trial-stage therapy**; the ESE/exon-3-skipping finding specifically dampens enthusiasm for splice-modulating ASOs against the founder allele.

Proposed Follow-up Experiments / Actions

1. **Generate a photoreceptor-specific disease model** — a *Kiz* knockout or p.Arg76* knock-in mouse, and/or patient iPSC-derived retinal organoids — to directly test outer-segment maintenance and connecting-cilium integrity (addresses the key inferred step).
2. **Functional connecting-cilium assays** in photoreceptor-like cells: quantify ciliary protein transport, outer-segment disc morphogenesis, and basal-body stability with and without kizuna.
3. **Test AAV-mediated KIZ gene augmentation** in a validated model, exploiting the clean loss-of-function mechanism that favors gene-replacement over gene-editing strategies.
4. **Minigene/transcript studies of non-founder alleles** to confirm whether the ESE/exon-3-skipping mechanism is unique to c.226C>T, which would refine ASO/splice-therapy prioritization.
5. **Deep natural-history study with standardized OCT/FAF/ERG endpoints** across diverse genotypes and ancestries to define progression trajectories and trial-ready biomarkers (EZ width, RPE-atrophy area).
6. **Carrier-screening expansion**: ensure p.Arg76* is included on Ashkenazi Jewish reproductive carrier panels and promote cascade testing and genetic counseling.
7. **Modifier-gene search** (e.g., whole-genome analysis across patients with discordant severity) to explain the comparatively mild phenotype.

Report generated from 7 confirmed findings across 15 reviewed papers (5 investigation iterations). Evidence spans human clinical genetics, human imaging cohorts, in vitro cell biology, and computational/population-database analysis, with source types indicated per claim.
